We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+16.39%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.34B
AUM Growth
+$471M
Cap. Flow
+$471M
Cap. Flow %
20.11%
Top 10 Hldgs %
49.6%
Holding
148
New
13
Increased
17
Reduced
7
Closed
13

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$59.2M
2
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$51.5M
3
SWTX
SpringWorks Therapeutics
SWTX
+$33.1M
4
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$25.3M
5
KLRS
Kalaris Therapeutics
KLRS
+$22M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$92.6M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$87.5M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$28.5M
4
CYTK icon
Cytokinetics
CYTK
+$13.2M
5
BLU
BELLUS Health Inc.
BLU
+$10.6M

Sector Composition

Rank Sector Weight
1 Healthcare 77.68%
2 Consumer Discretionary 2.9%
3 Financials 0.65%
4 Consumer Staples 0.17%
5 Industrials 0.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STOK icon
76
Stoke Therapeutics
STOK
$1.8B
$3.21M 0.14%
250,000
– –
CGEM icon
77
Cullinan Oncology
CGEM
$1.03B
$3.21M 0.14%
250,000
– –
ACIU icon
78
AC Immune
ACIU
$230M
$3.16M 0.13%
1,000,000
– –
BDTX icon
79
Black Diamond Therapeutics
BDTX
$94.5M
$2.78M 0.12%
1,646,517
– –
ZYME icon
80
Zymeworks
ZYME
$1.62B
$2.77M 0.12%
450,000
– –
PRAX icon
81
Praxis Precision Medicines
PRAX
$8.15B
$2.72M 0.12%
80,000
– –
BBIO icon
82
BridgeBio Pharma
BBIO
$16.5B
$2.48M 0.11%
250,000
– –
HOOK
83
DELISTED
HOOKIPA Pharma
HOOK
$2.48M 0.11%
184,962
– –
SANA icon
84
Sana Biotechnology
SANA
$852M
$2.4M 0.1%
400,000
– –
CYCN icon
85
Cyclerion Therapeutics
CYCN
$14.9M
$2.39M 0.1%
138,956
– –
AMAM
86
DELISTED
Ambrx Biopharma Inc
AMAM
$2.32M 0.1%
2,152,291
– –
NERV icon
87
Minerva Neurosciences
NERV
$193M
$2.31M 0.1%
+250,000
New +$1.48M
SNTI icon
88
Senti Biosciences Holdings
SNTI
$11.1M
$2.29M 0.1%
105,556
– –
FUSN
89
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$2.26M 0.1%
750,000
– –
APTX
90
DELISTED
Aptinyx Inc. Common Stock
APTX
$2.25M 0.1%
6,116,493
– –
LENZ
91
LENZ Therapeutics
LENZ
$178M
$2.22M 0.09%
100,000
– –
IMUX icon
92
Immunic
IMUX
$175M
$2.21M 0.09%
70,000
– –
VOR icon
93
Vor Biopharma
VOR
$1.06B
$2.19M 0.09%
27,500
– –
TIL icon
94
Instil Bio
TIL
$49.2M
$2.18M 0.09%
22,500
– –
TSHA icon
95
Taysha Gene Therapies
TSHA
$1.57B
$2.01M 0.09%
1,040,882
– –
GRTS
96
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$1.93M 0.08%
750,000
– –
ME
97
DELISTED
23andMe Holding Co
ME
$1.89M 0.08%
33,050
– –
YI
98
111 Inc
YI
$33.4M
$1.84M 0.08%
68,643
-27,992
-29% -$754K
IMMP
99
Immutep
IMMP
$56.7M
$1.56M 0.07%
1,000,000
– –
KNTE
100
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$1.49M 0.06%
125,000
– –
2 3
4
5 6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q3 2022 Portfolio in Review

As of Q3 2022, Artal Group held 148 positions worth $2.34B, up 25% from $1.87B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Artal Group deployed $471M of net new capital in Q3 2022, opening 13 new positions and adding to 17 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 1,000,000 shares worth $68.3M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 89% a quarter earlier, followed by Consumer Discretionary and Financials.

On the sell side, the largest reduction was argenx, an estimated $92.6M trimmed.

  • Artal Group's largest Q3 2022 buy was Apellis Pharmaceuticals: 1,000,000 shares worth $68.3M.
  • Artal Group added most to Lexicon Pharmaceuticals in Q3 2022, an estimated $51.5M increase.
  • Artal Group's biggest Q3 2022 reduction was argenx, cutting an estimated $92.6M.
  • Artal Group fully exited Alnylam Pharmaceuticals in Q3 2022, selling an estimated $87.5M.
  • Artal Group's ten largest holdings make up 50% of its $2.34B portfolio in Q3 2022.
  • Artal Group opened 13 new positions and closed 13 in Q3 2022.
  • Artal Group's portfolio value rose 25% quarter-over-quarter to $2.34B.

Based on Artal Group's 13F filing for Q3 2022, filed 14 Nov 2022.